Clinical Trial Update: APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors [Phase 4]

View source ↗

Summary

Clinical trial update for APAP-CYS protein adduct concentrations in patients undergoing liver-directed therapy for hepatic tumors; study withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Tumors
• Liver Cancer
• Liver Disease

Snippet

Sponsor: Denver Health and Hospital Authority | Conditions: Acetaminophen Exposure | Phase 4 | Status: WITHDRAWN